[{"id":"alpelisib","kind":"drug","name":"Alpelisib","route":"/drugs/alpelisib/","commit":"e03f56897d","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for thirty approved products that had none","file":"src/data/spikes/breast-hr-positive.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Alpelisib\" }]"}]},{"id":"alpelisib","kind":"drug","name":"Alpelisib","route":"/drugs/alpelisib/","commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"class"},{"field":"props"},{"field":"management"},{"field":"pairs"},{"field":"food"},{"field":"source"}]},{"id":"alpelisib","kind":"drug","name":"Alpelisib","route":"/drugs/alpelisib/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/breast-hr-positive.ts","type":"changed","fields":[{"field":"tldr","before":"\"The first PI3K drug for PIK3CA-mutant breast cancer (2019). Effective, but high blood sugar and rash limited its use, and newer drugs are displacing it.\"","after":"\"Alpelisib was the first PI3K drug for PIK3CA-mutant breast cancer (2019). It is effective, but high blood sugar and rash limited its use, and newer drugs are displacing it.\""}]},{"id":"alpelisib","kind":"drug","name":"Alpelisib","route":"/drugs/alpelisib/","commit":"f8e98e6f47","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: HR+/HER2- and HER2+ breast cancer to TNBC depth (structured trial outcomes, dosing, toxicity, regulatory events)","file":"src/data/spikes/breast-hr-positive.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"trials"},{"field":"pathways"}]}]